Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase III, Open-Label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects with Refractory Generalized Myasthenia Gravis (gMG)/ Alexion ECU-MG-302
Trial ID or NCT#
The purpose of this study is to determine if eculizumab is safe and effective for the treatment of patients with refractory gMG.
Srikanth Muppidi, MD
Contact us to find out if this trial is right for you.
About this Clinical Trial
Your Message Will Go ToLesly Welsh
Go Back To The Trial